Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)
Condition: Hurler Syndrome, Metachromatic Leukodystrophy (MLD), Globoid Cell Leukodystrophy (Krabbe) and Cerebral Adrenoleukodystrophy (cALD)Intervention: Drug: Umbilical cord blood transplantation with HSC835Sponsor: Novartis PharmaceuticalsNot yet recruiting - verified March 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials